What is GeneCapture?
GeneCapture has developed a groundbreaking portable technology solution, the CAPTURE Platform, designed for the rapid identification of pathogens and antibiotic susceptibility testing. This system operates without the need for refrigeration or specialized laboratory equipment, making it highly adaptable for use in various settings, including clinical environments, community health centers, agricultural applications, and even military field operations. The platform's ability to deliver actionable results within hours addresses a critical gap in current diagnostic capabilities, particularly in scenarios where swift decision-making is paramount for effective treatment and containment of infectious diseases.
How much funding has GeneCapture raised?
GeneCapture has raised a total of $85K across 2 funding rounds:
Debt
$35K
Debt
$50K
Debt (2021): $35K with participation from PPP
Debt (2026): $50K, investors not publicly disclosed
What's next for GeneCapture?
With the recent infusion of substantial expansion capital, GeneCapture is strategically positioned for significant scaling and market penetration. The company's Series B/C stage funding indicates a transition from product development to broader commercialization and operational expansion. Future initiatives will likely focus on enhancing the CAPTURE Platform's capabilities, expanding its regulatory approvals, and establishing robust distribution channels to reach a wider global market. This strategic investment will be crucial in solidifying GeneCapture's role as a leader in point-of-care diagnostics and in the ongoing fight against antimicrobial resistance.
See full GeneCapture company page
